Business Context and Reporting Period
Company: BioMarin Pharmaceutical Inc.
Filing Type: Form 8-K (Current Report)
Report Date: February 19, 2025
Reporting Period: Fourth quarter ended December 31, 2024
This filing announces the financial results for the fourth quarter of 2024. The detailed results are contained in a press release attached as Exhibit 99.1, which is incorporated by reference.
Key Financial Metrics
The provided text serves as a cover document for the results and does not contain specific numerical data. The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. Investors must refer to the attached press release (Exhibit 99.1) for these figures.
Material Changes
No material changes versus the prior comparable period are detailed in the text of this Form 8-K. The document solely references the announcement of the fourth-quarter results.
Guidance, Outlook, and Risks
Management Commentary: The filing incorporates the press release issued on February 19, 2025, by reference for management commentary, guidance, and outlook.
Risks and Contingencies: No specific risks or contingencies are listed in this excerpt. The filing includes a standard disclaimer stating that the information in the press release is not deemed "filed" under Section 18 of the Exchange Act and is not subject to the liabilities of that section.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific Q4 2024 revenue, net income, and cash flow figures.
- Verify full-year 2024 performance metrics and year-over-year growth rates in the attached press release.
- Check for updated 2025 financial guidance and operational outlook provided in the press release.
- Confirm any new product approvals, clinical trial updates, or regulatory developments mentioned in the full announcement.